We have located links that may give you full text access.
Implications of negative technetium 99m-labeled red blood cell scintigraphy in patients presenting with lower gastrointestinal bleeding.
American Journal of Surgery 2007 March
BACKGROUND: Lower gastrointestinal (GI) bleeding frequently recurs after negative technetium 99m-labeled red blood cell (RBC) scintigraphy.
METHODS: Between July 1, 1999 and July 31, 2005, 84 negative (99m)Tc-labeled RBC scintigrams were obtained for acute lower GI bleeding. Medical records were abstracted for age, gender, prior history of lower GI hemorrhage, length of hospitalization, initial hematocrit (Hct) and Hct nadir, transfusion requirements, cause of bleeding, use of anticoagulants and/or antiplatelet medications, and rebleeding episodes.
RESULTS: The overall rate of rebleeding was 27% (n = 23). There were no significant associations between any of the patient variables investigated and rebleeding.
CONCLUSIONS: Despite negative (99m)Tc-labeled RBC scintigraphy, more than 25% of patients experience recurrent lower GI bleeding. Patient age, bleeding source, use of anticoagulant/antiplatelet medications, length of stay, admission Hct, Hct nadir, transfusion requirements, and gender are not predictive of the patients who will rebleed.
METHODS: Between July 1, 1999 and July 31, 2005, 84 negative (99m)Tc-labeled RBC scintigrams were obtained for acute lower GI bleeding. Medical records were abstracted for age, gender, prior history of lower GI hemorrhage, length of hospitalization, initial hematocrit (Hct) and Hct nadir, transfusion requirements, cause of bleeding, use of anticoagulants and/or antiplatelet medications, and rebleeding episodes.
RESULTS: The overall rate of rebleeding was 27% (n = 23). There were no significant associations between any of the patient variables investigated and rebleeding.
CONCLUSIONS: Despite negative (99m)Tc-labeled RBC scintigraphy, more than 25% of patients experience recurrent lower GI bleeding. Patient age, bleeding source, use of anticoagulant/antiplatelet medications, length of stay, admission Hct, Hct nadir, transfusion requirements, and gender are not predictive of the patients who will rebleed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app